<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01993017</url>
  </required_header>
  <id_info>
    <org_study_id>AAAK9253</org_study_id>
    <secondary_id>1R01HL114924</secondary_id>
    <nct_id>NCT01993017</nct_id>
  </id_info>
  <brief_title>Comparison of Depression Identification After Acute Coronary Syndrome: Quality of Life and Cost Outcomes</brief_title>
  <acronym>CODIACSQoL</acronym>
  <official_title>Depression Screening RCT in ACS Patients: Quality of Life and Cost Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>HealthPartners Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kaiser Foundation Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine, in a randomized controlled trial, the benefits and
      costs of the American Heart Association's (AHA) advisory for depression screen and treatment
      of post-acute coronary syndrome patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with an acute coronary syndrome (ACS) and comorbid depression have a 2-fold higher
      risk for recurrent ACS and mortality, worse quality of life, and higher costs of care than
      nondepressed ACS patients. The strength of these observational findings prompted the American
      Heart Association (AHA) to advise that routine depression screening for ACS patients and
      referral for depression diagnosis and treatment as indicated occur. Unfortunately, there are
      no randomized controlled trials (RCT) to inform this potentially expensive screening
      recommendation. Additionally, screening guidelines/advisories in the absence of RCT evidence
      have recently been extensively criticized (and withdrawn). This poses a serious dilemma for
      clinicians, health care systems, and for health care policy leaders. A RCT is urgently needed
      to provide evidence for these different constituents about the costs and benefits of the AHA
      depression screen and treat algorithm.

      Two critical gaps in knowledge must be filled to determine if public health would be improved
      by the AHA strategy for depression screening in post-ACS patients: 1) Does this strategy
      improve quality-adjusted life years for patients with a recent ACS 2) Is the cost of
      providing depression screening and any type of depression treatment within the acceptable and
      typical amounts reimbursed for health care services? Our specific aim is to determine the
      quality-adjusted life year benefits and health care costs of following the AHA's advisory for
      depression screening and then referral for further diagnosis and treatment in post-ACS
      patients, if depression is found. To accomplish this aim, we will randomize patients from
      four different, geographically diverse health care systems to three different groups: 1) to
      the AHA depression screen and treat if depression is found algorithm (screen and treat
      intervention group) or: 2) to be screened and a primary care provider notified (screen and
      notify intervention group) or: 3) to receive no depression screening (control group).
      Health-related quality of life, depressive symptoms, and costs will be obtained from all
      patients, so that the benefits and the costs of these three different depression screening
      strategies can be compared.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">July 31, 2019</completion_date>
  <primary_completion_date type="Actual">July 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality-Adjusted Life Years (QALYs)</measure>
    <time_frame>Baseline, 6, 12 and 18 months</time_frame>
    <description>Change in QALYs from baseline through 18 months. QALYs are a generic measure of disease burden, including both the quality and the quantity of life lived. One QALY equates to one year in perfect health. To measure change in QALYs, utility scores [an overall assessment of well-being on a scale from 0 (death) to 1 (perfect health)], were estimated using the Short Form-6 dimension, with scores derived from responses to the 12-Item Short-Form Health Survey, version 2, at baseline and 6, 12, and 18 months. QALYs for the period from baseline to 18 months were then calculated as the area under the curve by linearly interpolating the utility scores at the 4 assessments. Change in QALYs was then obtained by subtracting the baseline QALY from the observed QALY for an 18-month period, where baseline QALY was calculated under the assumption that the baseline utility score remained constant during the 18-month period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Depression-free Days</measure>
    <time_frame>Baseline through 18 months</time_frame>
    <description>Depression-free days from baseline through 18 months post-randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost of Health Care Utilization</measure>
    <time_frame>Baseline through 18 months</time_frame>
    <description>Total cost of health care utilization from baseline through 18 months post-randomization
*Note: There is a delay in reporting this outcome due to time required to compile and analyze electronic health record data from 4 health care systems.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1501</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Depressive Symptoms</condition>
  <arm_group>
    <arm_group_label>AHA Depression Screen &amp; Treat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to this arm will complete the Depressive symptom screener (8-item Patient Health Questionnaire, PHQ-8) after randomization. Those with clinically significant score (&gt;=10) will be offered treatment. Treatment will be delivered according to participant preference, and will be managed according to &quot;stepped care&quot;. Stepped care includes, a) participant preference for either brief, cognitive behavioral therapy (CBT), delivered centrally by telephone, or antidepressant medication managed at the local site, or both, or neither, and b) review of progress at approximately 2-month intervals, with &quot;stepping up&quot; of care if sufficient progress is not being realized.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Depression Screen &amp; Notify Arm Type :</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants randomized to this arm will complete the depressive symptom screener (8-item Patient Health Questionnaire, PHQ-8) after randomization. Those with clinically significant score (&gt;=10) will have a letter sent to their primary care provider about their positive screen for depressive symptoms, with subsequent actions at the provider's discretion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Depression Screen</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants randomized to this arm will not complete a PHQ-8 assessment at randomization, and so will not be screened for depressive symptoms.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cognitive Behavioral Therapy (CBT)</intervention_name>
    <description>The main intervention is the impact of screening on quality of life and health care costs. CBT is provided only if depressive symptoms are detected and participant prefers this type of treatment.
CBT will be centrally telephone-administered by a trained CBT treatment specialist. The treatment specialist will work with local team members throughout a participant's involvement in the study, and will closely follow each participant until he or she has reached a requisite level of improvement .</description>
    <arm_group_label>AHA Depression Screen &amp; Treat</arm_group_label>
    <other_name>Problem Solving Therapy (PST)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antidepressant Medication</intervention_name>
    <description>The main intervention is the impact of screening on quality of life and health care costs. Antidepressant Medication is provided only if depressive symptoms are detected and patient prefers this type of treatment.
Antidepressants should be started at the lowest dose, but should be adjusted upward to be within the therapeutic range within 1 week, with further adjustment higher in the therapeutic range possible at 3-4 weeks. Dosage of the first medication selected will be in the therapeutic range by 3 weeks of the initial step, as tolerated.</description>
    <arm_group_label>AHA Depression Screen &amp; Treat</arm_group_label>
    <other_name>Sertraline</other_name>
    <other_name>Bupropion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard Care</intervention_name>
    <description>Participants will receive standard care from either their primary care provider (PCP), or PCP-referred mental health provider in one of the arms, IF depressive symptoms are detected.</description>
    <arm_group_label>Depression Screen &amp; Notify Arm Type :</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Depressive symptom screener</intervention_name>
    <description>8-item Patient Health Questionnaire, PHQ-8</description>
    <arm_group_label>AHA Depression Screen &amp; Treat</arm_group_label>
    <arm_group_label>Depression Screen &amp; Notify Arm Type :</arm_group_label>
    <other_name>PHQ-8</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <arm_group_label>No Depression Screen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  With a documented acute coronary syndrome (ACS) within the past 2-12 months

          -  Over the age of 21 years

          -  Has access to a phone

        Exclusion Criteria:

        Medical Exclusions:

          -  Terminal illness (life expectancy &lt;1 year as determined by physician/medical record)
             defined as, but not limited to:

          -  NYHA class IV, ACC class D CHF requiring inotropes or mechanical assist devices or
             critical aortic stenosis without plan for correction

          -  End-stage COPD/emphysema

          -  Advanced cirrhosis with encephalopathy, varices, severe ascites

          -  Severe rheumatologic diseases requiring frequent hospitalizations, and multiple
             cytotoxic agents and/or disease modifying drugs

          -  Metastatic pancreatic, esophageal, colorectal or stomach cancer

          -  Metastatic sarcoma, ovarian, melanoma or renal cell cancer

          -  Metastatic breast cancer with multiple recurrences despite treatment

          -  Advanced CNS malignancies

          -  Recurrent hematologic malignancies with multiple recurrences despite treatment

          -  Persistent AIDS, untreated or treated

        Psychiatric Exclusions:

          -  History of major depression

          -  Currently receiving depression treatment

          -  Dementia

          -  History of bipolar disorder

          -  History of psychosis

          -  History of suicide attempt or self-inflicted injuries

          -  Current alcohol or substance abuse

        Other Exclusions:

          -  Non-English and non-Spanish speaking
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ian M Kronish, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Health Partners institute for Research and Education</name>
      <address>
        <city>Bloomington</city>
        <state>Minnesota</state>
        <zip>55440</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Henderson</city>
        <state>North Carolina</state>
        <zip>27536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Foundation Research Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Moise N, Davidson KW, Cheung YKK, Clarke GN, Dolor RJ, Duer-Hefele J, Ladapo JA, Margolis KL, St Onge T, Parsons F, Retuerto J, Schmit KM, Thanataveerat A, Kronish IM. Rationale, design, and baseline data for a multicenter randomized clinical trial comparing depression screening strategies after acute coronary syndrome: The comparison of depression identification after acute Coronary Syndromes-Quality of Life and Cost Outcomes (CODIACS-QOL) trial. Contemp Clin Trials. 2019 Sep;84:105826. doi: 10.1016/j.cct.2019.105826. Epub 2019 Aug 13.</citation>
    <PMID>31419605</PMID>
  </reference>
  <results_reference>
    <citation>Kronish IM, Moise N, Cheung YK, Clarke GN, Dolor RJ, Duer-Hefele J, Margolis KL, St Onge T, Parsons F, Retuerto J, Thanataveerat A, Davidson KW. Effect of Depression Screening After Acute Coronary Syndromes on Quality of Life: The CODIACS-QoL Randomized Clinical Trial. JAMA Intern Med. 2019 Oct 21. doi: 10.1001/jamainternmed.2019.4518. [Epub ahead of print] Erratum in: JAMA Intern Med. 2019 Dec 1;179(12):1739.</citation>
    <PMID>31633746</PMID>
  </results_reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>November 19, 2013</study_first_submitted>
  <study_first_submitted_qc>November 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2013</study_first_posted>
  <results_first_submitted>October 24, 2019</results_first_submitted>
  <results_first_submitted_qc>December 3, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 18, 2019</results_first_posted>
  <last_update_submitted>December 3, 2019</last_update_submitted>
  <last_update_submitted_qc>December 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Ian Kronish</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Acute Coronary Syndrome</keyword>
  <keyword>Depressive Symptoms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Depression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupropion</mesh_term>
    <mesh_term>Sertraline</mesh_term>
    <mesh_term>Antidepressive Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>A deidentified data set and study materials will be provided upon request by other researchers.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 1, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/17/NCT01993017/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 1, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/17/NCT01993017/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period: November 1, 2013 to March 31, 2017
Recruitment sites: HealthPartners (Minneapolis, Minnesota), Duke University Health System (Durham, North Carolina), Kaiser Permanente Northwest (Portland, Oregon), and New Yorkâ€“Presbyterian/Columbia University Irving Medical Center (New York, New York)</recruitment_details>
      <pre_assignment_details>1 participant withdrew consent soon after randomization, and this participant's data was excluded from the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>AHA Depression Screen, Notify &amp; Treat</title>
          <description>Participants randomized to this arm will complete the Depressive symptom screener (8-item Patient Health Questionnaire, PHQ-8) after randomization. Those with clinically significant score (&gt;=10) will be offered treatment. Treatment will be delivered according to participant preference, and will be managed according to &quot;stepped care&quot;. Stepped care includes, a) participant preference for either brief, type of cognitive behavioral therapy (CBT) called problem-solving therapy (PST), delivered centrally by telephone, or antidepressant medication managed at the local site, or both, or neither, and b) review of progress at approximately 2-month intervals, with &quot;stepping up&quot; of care if sufficient progress is not being realized.</description>
        </group>
        <group group_id="P2">
          <title>Depression Screen &amp; Notify</title>
          <description>Participants randomized to this arm will complete the depressive symptom screener (8-item Patient Health Questionnaire, PHQ-8) after randomization. Those with clinically significant score (&gt;=10) will have a letter sent to their primary care provider about their positive screen for depressive symptoms, with subsequent actions at the provider's discretion.
Standard Care: Participants will receive standard care from either their primary care provider (PCP), or PCP-referred mental health provider in one of the arms, IF depressive symptoms are detected.
Depressive symptom screener: 8-item Patient Health Questionnaire, PHQ-8</description>
        </group>
        <group group_id="P3">
          <title>No Depression Screen</title>
          <description>Participants randomized to this arm will not complete a PHQ-8 assessment at randomization, and so will not be screened for depressive symptoms.
No intervention</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="499"/>
                <participants group_id="P2" count="501"/>
                <participants group_id="P3" count="500"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="393"/>
                <participants group_id="P2" count="411"/>
                <participants group_id="P3" count="421"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="106"/>
                <participants group_id="P2" count="90"/>
                <participants group_id="P3" count="79"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Could not be contacted</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="42"/>
                <participants group_id="P3" count="38"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Dropped out</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reasons</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ineligible after randomization</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AHA Depression Screen, Notify &amp; Treat</title>
          <description>Participants randomized to this arm will complete the Depressive symptom screener (8-item Patient Health Questionnaire, PHQ-8) after randomization. Those with clinically significant score (&gt;=10) will be offered treatment. Treatment will be delivered according to participant preference, and will be managed according to &quot;stepped care&quot;. Stepped care includes, a) participant preference for either a type of brief, cognitive behavioral therapy (CBT) called problem solving therapy (PST), delivered centrally by telephone, or antidepressant medication managed at the local site, or both, or neither, and b) review of progress at approximately 2-month intervals, with &quot;stepping up&quot; of care if sufficient progress is not being realized.</description>
        </group>
        <group group_id="B2">
          <title>Depression Screen &amp; Notify</title>
          <description>Participants randomized to this arm will complete the depressive symptom screener (8-item Patient Health Questionnaire, PHQ-8) after randomization. Those with clinically significant score (&gt;=10) will have a letter sent to their primary care provider about their positive screen for depressive symptoms, with subsequent actions at the provider's discretion.
Standard Care: Participants will receive standard care from either their primary care provider (PCP), or PCP-referred mental health provider in one of the arms, IF depressive symptoms are detected.
Depressive symptom screener: 8-item Patient Health Questionnaire, PHQ-8</description>
        </group>
        <group group_id="B3">
          <title>No Depression Screen</title>
          <description>Participants randomized to this arm will not complete a PHQ-8 assessment at randomization, and so will not be screened for depressive symptoms.
No intervention</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="499"/>
            <count group_id="B2" value="501"/>
            <count group_id="B3" value="500"/>
            <count group_id="B4" value="1500"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="499"/>
                    <count group_id="B2" value="501"/>
                    <count group_id="B3" value="500"/>
                    <count group_id="B4" value="1500"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.2" spread="11.3"/>
                    <measurement group_id="B2" value="65.8" spread="11.7"/>
                    <measurement group_id="B3" value="65.8" spread="11.7"/>
                    <measurement group_id="B4" value="65.9" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="499"/>
                    <count group_id="B2" value="501"/>
                    <count group_id="B3" value="500"/>
                    <count group_id="B4" value="1500"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="142"/>
                    <measurement group_id="B2" value="137"/>
                    <measurement group_id="B3" value="145"/>
                    <measurement group_id="B4" value="424"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="357"/>
                    <measurement group_id="B2" value="364"/>
                    <measurement group_id="B3" value="355"/>
                    <measurement group_id="B4" value="1076"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="499"/>
                    <count group_id="B2" value="501"/>
                    <count group_id="B3" value="500"/>
                    <count group_id="B4" value="1500"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="88"/>
                    <measurement group_id="B3" value="74"/>
                    <measurement group_id="B4" value="244"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="406"/>
                    <measurement group_id="B2" value="402"/>
                    <measurement group_id="B3" value="410"/>
                    <measurement group_id="B4" value="1218"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="499"/>
                    <count group_id="B2" value="501"/>
                    <count group_id="B3" value="500"/>
                    <count group_id="B4" value="1500"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="353"/>
                    <measurement group_id="B2" value="368"/>
                    <measurement group_id="B3" value="359"/>
                    <measurement group_id="B4" value="1080"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="499"/>
                    <count group_id="B2" value="501"/>
                    <count group_id="B3" value="500"/>
                    <count group_id="B4" value="1500"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="46"/>
                    <measurement group_id="B4" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="499"/>
                    <count group_id="B2" value="501"/>
                    <count group_id="B3" value="500"/>
                    <count group_id="B4" value="1500"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="85"/>
                    <measurement group_id="B4" value="259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Refused or unknown</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="499"/>
                    <count group_id="B2" value="501"/>
                    <count group_id="B3" value="500"/>
                    <count group_id="B4" value="1500"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="499"/>
                    <count group_id="B2" value="501"/>
                    <count group_id="B3" value="500"/>
                    <count group_id="B4" value="1500"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="499"/>
                    <measurement group_id="B2" value="501"/>
                    <measurement group_id="B3" value="500"/>
                    <measurement group_id="B4" value="1500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PHQ-8 Score &gt;= 10</title>
          <population>PHQ-8 data were not collected at Baseline in the &quot;No Depression Screen&quot; Arm/Group).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="494"/>
                    <count group_id="B2" value="501"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="995"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B4" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Quality-Adjusted Life Years (QALYs)</title>
        <description>Change in QALYs from baseline through 18 months. QALYs are a generic measure of disease burden, including both the quality and the quantity of life lived. One QALY equates to one year in perfect health. To measure change in QALYs, utility scores [an overall assessment of well-being on a scale from 0 (death) to 1 (perfect health)], were estimated using the Short Form-6 dimension, with scores derived from responses to the 12-Item Short-Form Health Survey, version 2, at baseline and 6, 12, and 18 months. QALYs for the period from baseline to 18 months were then calculated as the area under the curve by linearly interpolating the utility scores at the 4 assessments. Change in QALYs was then obtained by subtracting the baseline QALY from the observed QALY for an 18-month period, where baseline QALY was calculated under the assumption that the baseline utility score remained constant during the 18-month period.</description>
        <time_frame>Baseline, 6, 12 and 18 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AHA Depression Screen, Notify &amp; Treat</title>
            <description>Participants randomized to this arm will complete the Depressive symptom screener (8-item Patient Health Questionnaire, PHQ-8) after randomization. Those with clinically significant score (&gt;=10) will be offered treatment. Treatment will be delivered according to participant preference, and will be managed according to &quot;stepped care&quot;. Stepped care includes, a) participant preference for either brief, type of cognitive behavioral therapy (CBT) called problem-solving therapy (PST), delivered centrally by telephone, or antidepressant medication managed at the local site, or both, or neither, and b) review of progress at approximately 2-month intervals, with &quot;stepping up&quot; of care if sufficient progress is not being realized.</description>
          </group>
          <group group_id="O2">
            <title>Depression Screen &amp; Notify</title>
            <description>Participants randomized to this arm will complete the depressive symptom screener (8-item Patient Health Questionnaire, PHQ-8) after randomization. Those with clinically significant score (&gt;=10) will have a letter sent to their primary care provider about their positive screen for depressive symptoms, with subsequent actions at the provider's discretion.
Standard Care: Participants will receive standard care from either their primary care provider (PCP), or PCP-referred mental health provider in one of the arms, IF depressive symptoms are detected.
Depressive symptom screener: 8-item Patient Health Questionnaire, PHQ-8</description>
          </group>
          <group group_id="O3">
            <title>No Depression Screen</title>
            <description>Participants randomized to this arm will not complete a PHQ-8 assessment at randomization, and so will not be screened for depressive symptoms.
No intervention</description>
          </group>
        </group_list>
        <measure>
          <title>Quality-Adjusted Life Years (QALYs)</title>
          <description>Change in QALYs from baseline through 18 months. QALYs are a generic measure of disease burden, including both the quality and the quantity of life lived. One QALY equates to one year in perfect health. To measure change in QALYs, utility scores [an overall assessment of well-being on a scale from 0 (death) to 1 (perfect health)], were estimated using the Short Form-6 dimension, with scores derived from responses to the 12-Item Short-Form Health Survey, version 2, at baseline and 6, 12, and 18 months. QALYs for the period from baseline to 18 months were then calculated as the area under the curve by linearly interpolating the utility scores at the 4 assessments. Change in QALYs was then obtained by subtracting the baseline QALY from the observed QALY for an 18-month period, where baseline QALY was calculated under the assumption that the baseline utility score remained constant during the 18-month period.</description>
          <units>quality-adjusted life years (QALYs)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="499"/>
                <count group_id="O2" value="501"/>
                <count group_id="O3" value="500"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" spread="0.20"/>
                    <measurement group_id="O2" value="-0.06" spread="0.20"/>
                    <measurement group_id="O3" value="-0.06" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>We determined that a sample size per group of 500, assuming 5% loss to follow-up, would yield 80% power for a 2-sided t test at the 5% level. These calculations were based on an assumed SD for QALYs of 0.17, expected prevalence of screening-detected depression of 20%, and assumed net improvement in QALYs of 0.155 over 18 months for individuals with depression who received treatment for depression in the Screen, Notify, and Treat group.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.98</p_value>
            <p_value_desc>A 2-step gatekeeping test procedure was used. An omnibus F test using ANOVA comparing the 3 groups was first performed. Pairwise comparisons using a 2-sided t test at 5% nominal significance were planned only if the omnibus F test had a P value &lt;.05.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Depression-free Days</title>
        <description>Depression-free days from baseline through 18 months post-randomization</description>
        <time_frame>Baseline through 18 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AHA Depression Screen, Notify &amp; Treat</title>
            <description>Participants randomized to this arm will complete the Depressive symptom screener (8-item Patient Health Questionnaire, PHQ-8) after randomization. Those with clinically significant score (&gt;=10) will be offered treatment. Treatment will be delivered according to participant preference, and will be managed according to &quot;stepped care&quot;. Stepped care includes, a) participant preference for either brief, type of cognitive behavioral therapy (CBT) called problem-solving therapy (PST), delivered centrally by telephone, or antidepressant medication managed at the local site, or both, or neither, and b) review of progress at approximately 2-month intervals, with &quot;stepping up&quot; of care if sufficient progress is not being realized.</description>
          </group>
          <group group_id="O2">
            <title>Depression Screen &amp; Notify</title>
            <description>Participants randomized to this arm will complete the depressive symptom screener (8-item Patient Health Questionnaire, PHQ-8) after randomization. Those with clinically significant score (&gt;=10) will have a letter sent to their primary care provider about their positive screen for depressive symptoms, with subsequent actions at the provider's discretion.
Standard Care: Participants will receive standard care from either their primary care provider (PCP), or PCP-referred mental health provider in one of the arms, IF depressive symptoms are detected.
Depressive symptom screener: 8-item Patient Health Questionnaire, PHQ-8</description>
          </group>
          <group group_id="O3">
            <title>No Depression Screen</title>
            <description>Participants randomized to this arm will not complete a PHQ-8 assessment at randomization, and so will not be screened for depressive symptoms.
No intervention</description>
          </group>
        </group_list>
        <measure>
          <title>Depression-free Days</title>
          <description>Depression-free days from baseline through 18 months post-randomization</description>
          <units>cumulative depression-free days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="499"/>
                <count group_id="O2" value="501"/>
                <count group_id="O3" value="500"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="343.1" spread="179.0"/>
                    <measurement group_id="O2" value="351.3" spread="175.0"/>
                    <measurement group_id="O3" value="339.0" spread="176.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cost of Health Care Utilization</title>
        <description>Total cost of health care utilization from baseline through 18 months post-randomization
*Note: There is a delay in reporting this outcome due to time required to compile and analyze electronic health record data from 4 health care systems.</description>
        <time_frame>Baseline through 18 months</time_frame>
        <posting_date>03/2020</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>18 months</time_frame>
      <desc>Serious Adverse Events and mortality were assessed in all participants.
Other Adverse Events were assessed using a self-report instrument at 6-mo, 12-mo, and 18-mo. As not all participants were reached to complete this questionnaire, fewer participants were assessed for Other Adverse Events than for Serious Adverse Events and mortality. Also, the number of participants who were assessed for Other Adverse Events varies according to the time period of assessment.</desc>
      <group_list>
        <group group_id="E1">
          <title>AHA Depression Screen, Notify &amp; Treat</title>
          <description>Participants randomized to this arm will complete the Depressive symptom screener (8-item Patient Health Questionnaire, PHQ-8) after randomization. Those with clinically significant score (&gt;=10) will be offered treatment. Treatment will be delivered according to participant preference, and will be managed according to &quot;stepped care&quot;. Stepped care includes, a) participant preference for either brief, type of cognitive behavioral therapy (CBT) called problem-solving therapy (PST), delivered centrally by telephone, or antidepressant medication managed at the local site, or both, or neither, and b) review of progress at approximately 2-month intervals, with &quot;stepping up&quot; of care if sufficient progress is not being realized.</description>
        </group>
        <group group_id="E2">
          <title>Depression Screen &amp; Notify</title>
          <description>Participants randomized to this arm will complete the depressive symptom screener (8-item Patient Health Questionnaire, PHQ-8) after randomization. Those with clinically significant score (&gt;=10) will have a letter sent to their primary care provider about their positive screen for depressive symptoms, with subsequent actions at the provider's discretion.
Standard Care: Participants will receive standard care from either their primary care provider (PCP), or PCP-referred mental health provider in one of the arms, IF depressive symptoms are detected.
Depressive symptom screener: 8-item Patient Health Questionnaire, PHQ-8</description>
        </group>
        <group group_id="E3">
          <title>No Depression Screen</title>
          <description>Participants randomized to this arm will not complete a PHQ-8 assessment at randomization, and so will not be screened for depressive symptoms.
No intervention</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="501"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="499"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="386" subjects_at_risk="450"/>
                <counts group_id="E2" subjects_affected="398" subjects_at_risk="455"/>
                <counts group_id="E3" subjects_affected="399" subjects_at_risk="458"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Any bleeding at 6 mo</sub_title>
                <description>Self-report of any bleeding</description>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="450"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="455"/>
                <counts group_id="E3" subjects_affected="72" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Any bleeding at 12 mo</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="423"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="429"/>
                <counts group_id="E3" subjects_affected="50" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Any bleeding at 18 mo</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="394"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="419"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal upset at 6 mo</sub_title>
                <description>Self-report of gastrointestinal upset</description>
                <counts group_id="E1" subjects_affected="128" subjects_at_risk="450"/>
                <counts group_id="E2" subjects_affected="116" subjects_at_risk="454"/>
                <counts group_id="E3" subjects_affected="112" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Gastrointestinal upset at 12 mo</sub_title>
                <counts group_id="E1" subjects_affected="95" subjects_at_risk="423"/>
                <counts group_id="E2" subjects_affected="95" subjects_at_risk="431"/>
                <counts group_id="E3" subjects_affected="107" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Gastrointestinal upset at 18 mo</sub_title>
                <counts group_id="E1" subjects_affected="98" subjects_at_risk="394"/>
                <counts group_id="E2" subjects_affected="99" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="100" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Increased appetite at 6 mo</sub_title>
                <description>Self-report of increased appetite</description>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="450"/>
                <counts group_id="E2" subjects_affected="84" subjects_at_risk="455"/>
                <counts group_id="E3" subjects_affected="91" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Decreased appetite at 6 mo</sub_title>
                <description>Self-report of decreased appetite</description>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="450"/>
                <counts group_id="E2" subjects_affected="74" subjects_at_risk="455"/>
                <counts group_id="E3" subjects_affected="76" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Drowsiness at 6 mo</sub_title>
                <description>Self-report of drowsiness</description>
                <counts group_id="E1" subjects_affected="218" subjects_at_risk="450"/>
                <counts group_id="E2" subjects_affected="212" subjects_at_risk="455"/>
                <counts group_id="E3" subjects_affected="217" subjects_at_risk="458"/>
              </event>
              <event>
                <sub_title>Increased appetite at 12 mo</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="423"/>
                <counts group_id="E2" subjects_affected="77" subjects_at_risk="431"/>
                <counts group_id="E3" subjects_affected="76" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Decreased appetite at 12 mo</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="423"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="431"/>
                <counts group_id="E3" subjects_affected="76" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Drowsiness at 12 mo</sub_title>
                <counts group_id="E1" subjects_affected="179" subjects_at_risk="423"/>
                <counts group_id="E2" subjects_affected="187" subjects_at_risk="431"/>
                <counts group_id="E3" subjects_affected="198" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Increased appetite at 18 mo</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="394"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="60" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Decreased appetite at 18 mo</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="394"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="62" subjects_at_risk="419"/>
              </event>
              <event>
                <sub_title>Drowsiness at 18 mo</sub_title>
                <counts group_id="E1" subjects_affected="152" subjects_at_risk="394"/>
                <counts group_id="E2" subjects_affected="177" subjects_at_risk="410"/>
                <counts group_id="E3" subjects_affected="171" subjects_at_risk="419"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ian Kronish, MD, MPH, Principal Investigator</name_or_title>
      <organization>Center for Behavioral Cardiovascular Health</organization>
      <phone>212-342-1335</phone>
      <email>ik2293@columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

